by healthadvances Posted on May 16, 2023 Winning the China Market: A Review of NRDL Inclusions Read More
by healthadvances Posted on July 21, 2021 India, the Generic Manufacturing Powerhouse, Biosimilar Next? Read More
by healthadvances Posted on April 8, 2020April 13, 2020 How COVID-19 May Redirect US Healthcare Reform Priorities Read More
by healthadvances Posted on October 29, 2019April 13, 2020 Health Advances Presentation at AMCP Nexus: Costs of Mandating Blister Packaging for Opioids Read More
by healthadvances Posted on April 16, 2019April 13, 2020 Better Market Access in China – Government Improves Pricing and Reimbursement Environment Read More
by healthadvances Posted on April 7, 2019April 13, 2020 Keytruda, a case study for the improved regulatory environment in China Read More
by healthadvances Posted on March 27, 2019April 13, 2020 Improvements in China Drug Registration – Opening the Door to the China Market for Global BioPharma Read More
by healthadvances Posted on November 9, 2018April 13, 2020 Health Advances Presentation at ISPOR: An Initial Analysis of the Cost-Based Pricing Revisions in Japan Read More
by healthadvances Posted on November 9, 2018April 13, 2020 Health Advances Presentation at ISPOR: Findings from the First Five Years of the NICE HST Program for Ultra Rare Conditions Read More
by healthadvances Posted on August 23, 2018April 13, 2020 Disease Management Programs (DMPs) in Germany: The Importance of Guideline Inclusion for Chronic Therapies Read More
by healthadvances Posted on May 3, 2018April 15, 2020 Patient Advocacy Groups as a Strategy for Orphan Drug Access in the UK Read More
by healthadvances Posted on January 16, 2018April 15, 2020 PART 2: 2018 Wildcards – Healthcare Regulation and Models of Care Read More
by healthadvances Posted on June 25, 2015April 15, 2020 Drug Pricing & Reimbursement at the Boston CMO Network Read More
by healthadvances Posted on June 22, 2015April 15, 2020 Pricing Orphan and Specialty Drugs-Insights from the World Orphan Drug Congress & ISPOR Read More
